Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Nutritional supplements and stroke prevention

This article was originally published in The Tan Sheet

Executive Summary

Nutritional supplements and stroke prevention: Bowman Gray University will lead a 36-center randomized clinical trial to determine whether multiple nutrient supplements can prevent occurrence of second stroke in 3,600 patients. The study will be initiated within a few months, Winston Salem, N.C.-based Bowman Gray says. Funded by a $20 mil. grant from the National Institute of Neurological Diseases & Stroke, the five-year trial will be led by Bowman Gray's James Toole, MD. Patients who have had one mild stroke will be randomized to receive either a standard or large amount of nutritional supplementation and examined every six months for two years, with two years of follow-up. The final protocol and the location of the 36 trial sites should be decided by December...

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

OM008605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel